HurlutinTM Lu-177
/ Advanced Innovative Partners
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 05, 2024
Heroine01: A Phase I/II Multicenter, Open-Label Study of Lu-177-αvβ3-IAC, for the Treatment of Angiogenic Breast Cancer Patients.
(clinicaltrials.gov)
- P1/2 | N=100 | Not yet recruiting | Sponsor: Advanced Imaging Projects, LLC | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Aug 2024 ➔ Aug 2025
Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1